N/A
N=18
PK Analysis of Moxifloxacin in the Treatment of CAP
Pneumonia
Bottom Line
View on ClinicalTrials.gov: NCT01983839 ↗Enrolled (actual)
18
Serious AEs
—
Results posted
Apr 2015
Primary outcome: Primary: Total Peak Plasma Concentration (Cmax) — 3.99 mg/L
Study Design & Population
- Study type
- Observational
- Phase
- N/A
- Interventions
- —
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Aarhus
- Primary completion
- Oct 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Total Peak Plasma Concentration (Cmax) |
3.99 | — |
| PRIMARY Area Under the Free Concentration-time Curve (fAUC0-24) |
32.78 | — |
Summary
At the Department of Infectious Diseases, Aarhus Denmark, moxifloxacin is used in the empirical treatment of severe community-acquired pneumonia (CAP). This study was designed to determine the pharmacokinetics of moxifloxacin 400 mg/day to patients treated empirically for CAP. To accomplish this aim, we established a pharmacokinetic population model. This approach was adopted with the dual purpose of assessing the potential efficacy of the drug and performing Monte-Carlo simulations to characterize the maximal MICs for which recommended pharmacokinetic-pharmacodynamic (PK-PD) targets are obtained for pathogens commonly known to cause CAP.
Eligibility Criteria
Inclusion Criteria
- Patients with community-acquired pneumonia, treated with moxifloxacin
Exclusion Criteria
- Under 18 years of age
Data sourced from ClinicalTrials.gov (NCT01983839). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.